#M&A – HEALTHCARE INSIGHTS

Key Development Australia-based Telix Pharmaceuticals has entered into a definitive agreement to acquire German radiopharmaceutical manufacturer ITM Isotope Technologies Munich... Read more

Tag: #M&A

MERCK’S $1.3 BILLION SILENCE THERAPEUTICS DEAL: WHY RNAi PLATFORMS ARE BECOMING STRATEGIC ASSETS IN PHARMACEUTICAL M&A

UNILEVER EXITS WELLY: WHY CONSUMER HEALTHCARE M&A IS SHIFTING FROM BRAND OWNERSHIP TO PORTFOLIO PRODUCTIVITY

STERIS PAYS $2.1 BILLION FOR XODUS: MEDTECH COMPETITION IS SHIFTING FROM “SELLING EQUIPMENT” TO OWNING MORE ECONOMICS IN EVERY PROCEDURE

MCKESSON–CD&R STRIKE $5.8 BILLION OPTION CARE HEALTH DEAL: THE SPECIALTY PHARMA RACE IS MOVING FROM DRUG DISTRIBUTION TO CONTROL OF THE TREATMENT JOURNEY

TELIX’S $1.65 BILLION ACQUISITION OF ITM: SECURING INFRASTRUCTURE SUPREMACY IN RADIOPHARMACEUTICALS

Clinical Research Organization (CRO) Consolidation: Fortrea Acquires Worldwide Clinical Trials’ Early Phase Business in $45M Transaction – Absorbing Three Texas Facilities and 200 Inpatient Beds to Expand Global Capacity to 576 Beds

Medical-Grade Aesthetics & Private Equity Exits: Blackstone Explores $2 Billion Sale of ZO Skin Health – Premium Physician-Dispensed Skincare In High Demand Among Strategic Healthcare and Beauty Acquirers

Immunology M&A & Precision Autoimmunity: Eli Lilly to Acquire Merida Biosciences for Up to $2.88 Billion in Cash – Bolstering Thyroid Autoimmune Pipeline (MER511) to Diversify Beyond Incretin Blockbusters

Consumer Health Antitrust Clearance: Australian Competition and Consumer Commission (ACCC) Approves Kimberly-Clark’s $40 Billion Takeover of Kenvue Conditioned on Divestment of Carefree® and Stayfree® Period Care Brands

Facebook

Map

Online Members